[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Knight LA, Di Nicolantonio F, Whitehouse P, Mercer S, Sharma S, Glaysher S, Johnson P, Cree IA: The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer; 2004 Nov 23;4:83
University of Turin Instituional Repository AperTO. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
  • METHODS: In this study we have used a standardised ATP-based tumour chemosensitivity assay (ATP-TCA) to measure the activity of gefitinib alone or in combination with different cytotoxic drugs (cisplatin, gemcitabine, oxaliplatin and treosulfan) against a variety of solid tumours (n = 86), including breast, colorectal, oesophageal and ovarian cancer, carcinoma of unknown primary site, cutaneous and uveal melanoma, non-small cell lung cancer (NSCLC) and sarcoma.
  • To allow comparison between samples the IndexSUM was calculated based on the percentage tumour growth inhibition (TGI) at each test drug concentration (TDC).
  • CONCLUSION: The in vitro model suggests that gefitinib may have differential effects in response to concomitant cytotoxic chemotherapy with the agents tested during this study.
  • The mechanism involved may relate to the effect of TKIs on growth rate versus their effect on the ability of the cell to survive the stimulus to apoptosis produced by chemotherapy.
  • [MeSH-major] Busulfan / analogs & derivatives. Deoxycytidine / analogs & derivatives. Neoplasms / drug therapy. Quinazolines / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenosine Triphosphate / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Colorectal Neoplasms / drug therapy. Drug Screening Assays, Antitumor / methods. Female. Humans. Melanoma / drug therapy. Neoplasms, Unknown Primary / drug therapy. Organoplatinum Compounds / administration & dosage. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Skin Neoplasms / drug therapy. Stomach Neoplasms / drug therapy. Uveal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TREOSULFAN .
  • Hazardous Substances Data Bank. BUSULFAN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 1993 Jun;19(3):242-9 [8314382.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):241-50 [10454201.001]
  • [Cites] Lancet. 1996 Apr 20;347(9008):1066-71 [8602056.001]
  • [Cites] Anticancer Drugs. 1996 Aug;7(6):630-5 [8913430.001]
  • [Cites] Anticancer Drugs. 1998 Jan;9(1):51-7 [9491792.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):258-63 [10785475.001]
  • [Cites] Biochem J. 2000 Oct 15;351 Pt 2:289-305 [11023813.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4885-92 [11156248.001]
  • [Cites] Melanoma Res. 2001 Dec;11(6):601-9 [11725206.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2240-50 [11980995.001]
  • [Cites] Anticancer Drugs. 2002 Jul;13(6):625-30 [12172508.001]
  • [Cites] Oncologist. 2002;7 Suppl 4:16-24 [12202784.001]
  • [Cites] Oncologist. 2002;7 Suppl 4:31-9 [12202786.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5749-54 [12384534.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2658-63 [12860941.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] J Cell Physiol. 2004 Feb;198(2):259-68 [14603528.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):777-84 [14990632.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):785-94 [14990633.001]
  • [Cites] BMC Cancer. 2003 Jul 3;3:19 [12841853.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13513-8 [9811831.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1487-93 [10188895.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5276-82 [7585588.001]
  • (PMID = 15560844.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Quinazolines; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 8L70Q75FXE / Adenosine Triphosphate; B76N6SBZ8R / gemcitabine; CO61ER3EPI / treosulfan; G1LN9045DK / Busulfan; Q20Q21Q62J / Cisplatin; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ PMC535559
  •  go-up   go-down


2. Terrier-Lacombe MJ, Guillou L, Chibon F, Gallagher G, Benhattar J, Terrier P, Ranchère D, Coindre JM: Superficial primitive Ewing's sarcoma: a clinicopathologic and molecular cytogenetic analysis of 14 cases. Mod Pathol; 2009 Jan;22(1):87-94
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial primitive Ewing's sarcoma: a clinicopathologic and molecular cytogenetic analysis of 14 cases.
  • In the skin and subcutis, the diagnosis is often difficult, and performing molecular cytogenetic techniques may be helpful.
  • Clinical, histological, immunohistochemical, molecular cytogenetic, therapeutic, and follow-up data are reported.
  • They were all small round-cell proliferations with a strong membranous positivity for CD99.
  • Ewing's sarcoma translocations/fusion gene transcripts were detected in eight cases, both by FISH and reverse transcriptase (RT)-PCR.
  • Chemotherapy was given in ten patients and radiotherapy in six.
  • Given the difficulty of the diagnosis and the importance of an adapted treatment, a confirmation of the diagnosis by molecular or cytogenetic techniques is recommended when dealing with a superficial tumor.
  • [MeSH-major] Sarcoma, Ewing / genetics. Sarcoma, Ewing / pathology. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / biosynthesis. Calmodulin-Binding Proteins / genetics. Cell Adhesion Molecules / biosynthesis. Child. Cytogenetic Analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oncogene Proteins, Fusion / genetics. RNA-Binding Proteins / genetics. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18820660.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Calmodulin-Binding Proteins; 0 / Cell Adhesion Molecules; 0 / EWSR1 protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA-Binding Proteins
  •  go-up   go-down


3. Unger C, Häring B, Medinger M, Drevs J, Steinbild S, Kratz F, Mross K: Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res; 2007 Aug 15;13(16):4858-66
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Treatment with DOXO-EMCH was well tolerated up to 200 mg/m2 without manifestation of drug-related side effects.
  • CONCLUSIONS: DOXO-EMCH showed a good safety profile and was able to induce tumor regressions in tumor types known to be anthracycline-sensitive tumors, such as breast cancer, small cell lung cancer, and sarcoma.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Doxorubicin / analogs & derivatives. Hydrazones / adverse effects. Neoplasms / drug therapy. Prodrugs / adverse effects
  • [MeSH-minor] Adult. Aged. Female. Heart / drug effects. Humans. Male. Maximum Tolerated Dose. Middle Aged. Skin / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17699865.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Hydrazones; 0 / Prodrugs; 151038-96-9 / doxorubicin(6-maleimidocaproyl)hydrazone; 80168379AG / Doxorubicin
  •  go-up   go-down


Advertisement
4. Al Zolibani AA, Al Robaee AA: Primary palmoplantar Kaposi's sarcoma: an unusual presentation. Skinmed; 2006 Sep-Oct;5(5):248-9
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary palmoplantar Kaposi's sarcoma: an unusual presentation.
  • These lesions started as small faint purple-red macules and gradually increased in number and size.
  • A systemic clinical examination was unremarkable other than an amputation of the distal phalanx of the left index.
  • Result of routine laboratory investigations including complete blood cell count, liver and renal function tests, and chest x-ray were normal.
  • A punch skin biopsy taken from the left palm showed acanthosis and spongiosis in the epidermis.
  • The treatment options, including cryotherapy and intralesional chemotherapy, were discussed with the patient but, unfortunately, he did not return for follow-up.
  • [MeSH-major] Foot Diseases / pathology. Hand. Sarcoma, Kaposi / pathology

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957440.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy.
  • Histiocytic sarcoma is a rare malignant neoplasm that occurs in lymph nodes, skin, and the gastrointestinal tract.
  • Only small numbers of bona fide examples exist in the world literature; cases arising primarily at extranodal sites are not well described and often seem to go unrecognized.
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • At the last follow-up, 2 patients have died of disseminated disease, 4 and 5 months following initial diagnosis.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Metastatic carcinoma, metastatic melanoma, and large cell non-Hodgkin lymphomas should be excluded by immunohistochemistry.
  • Histiocytic sarcoma has the potential for an aggressive clinical course, most often with lymph node involvement.
  • [MeSH-major] Sarcoma / pathology

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Taylor F, Gear R, Hoather T, Dobson J: Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases. J Small Anim Pract; 2009 Jun;50(6):284-9
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.
  • OBJECTIVES: To evaluate the response of measurable canine mast cell tumours unsuitable for other treatment modalities to a chemotherapy protocol comprising chlorambucil and prednisolone.
  • METHODS: Dogs bearing measurable mast cell tumours, unsuitable for treatment by surgery or radiotherapy, were treated with orally administered prednisolone and chlorambucil, and their responses assessed.
  • RESULTS: Twenty-one dogs were enrolled in the study; 13 had intermediate-grade mast cell tumour, six were high grade and two were diagnosed by cytology alone.
  • Median progression-free interval for the eight responders was 533 days, and median survival time for all dogs in the study was 140 days.
  • Progression-free interval and median survival time were not influenced by the age, sex, weight or neutering status of the patient, by the grade or stage of the tumour or whether the patient had single or multiple tumours.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dog Diseases / drug therapy. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Chlorambucil / therapeutic use. Disease Progression. Dogs. Female. Lymphatic Metastasis. Male. Neoplasm Staging / veterinary. Prednisolone / therapeutic use. Prospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19527421.001).
  • [ISSN] 1748-5827
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 18D0SL7309 / Chlorambucil; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


7. Khanna C, Gordon I: Catching cancer by the tail: new perspectives on the use of kinase inhibitors. Clin Cancer Res; 2009 Jun 1;15(11):3645-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this issue of Clinical Cancer Research, London and colleagues evaluate a small molecule multiple-targeted tyrosine kinase inhibitor in dogs with c-kit driven skin cancer.
  • The study represents another example of opportunities to include pet dogs in studies that improve our understanding of human cancer biology and therapy.
  • [MeSH-major] Dog Diseases / drug therapy. Indoles / therapeutic use. Mast-Cell Sarcoma / drug therapy. Pyrroles / therapeutic use. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
  • [MeSH-minor] Animals. Dogs. Neoplasm Recurrence, Local. Random Allocation. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Cancer Res. 2009 Jun 1;15(11):3856-65 [19470739.001]
  • (PMID = 19470723.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / Pyrroles; 24F9PF7J3R / toceranib phosphate; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


8. Kasper B, Ho AD, Egerer G: Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma? Oncology; 2005;68(2-3):115-21
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?
  • Sarcomas represent a rare and heterogeneous disease, and the prognosis of patients with unresectable or advanced metastatic bone and especially soft-tissue sarcomas remains poor, with a disease-free survival of less than 10% at 5 years.
  • Although combination therapy with different chemotherapeutic substances results in higher response rates, superiority against single-agent chemotherapy in terms of survival has not been demonstrated yet.
  • Regarding anthracyclines, and ifosfamide in particular, a dose-response relationship has been shown, and high-dose chemotherapy with stem cell support has also been evaluated by several investigators.
  • However, all studies comprised small patient cohorts and included very heterogeneous histological subtypes of soft-tissue sarcoma.
  • Nevertheless, higher doses of chemotherapy result in higher response rates possibly correlating with longer survival.
  • Finally, well-designed randomized trials should be performed, preferably in younger patients and in the context of an interdisciplinary treatment approach.
  • In this review, we provide an overview of the literature concerning high-dose chemotherapy with hematopoietic stem cell support in the treatment of bone and soft-tissue sarcomas.
  • On the basis of our own data, we would like to emphasize the importance of high-dose chemotherapy in the treatment of sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Osteosarcoma / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Neoplasms / drug therapy. Bone Neoplasms / drug therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Hematopoietic Stem Cell Transplantation. Humans. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Male. Middle Aged. Retroperitoneal Neoplasms / drug therapy. Retrospective Studies. Skin Neoplasms / drug therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15886503.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 35
  •  go-up   go-down


9. Khalid S, Adil SN, Vaziri IA: Granulocytic sarcoma in the absence of acute myeloid leukemia: a case report. Indian J Pathol Microbiol; 2007 Jan;50(1):88-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma in the absence of acute myeloid leukemia: a case report.
  • Granulocytic sarcoma is an extramedullary tumor composed of immature granulocytic precursor cells.
  • The most common sites of presentation are bone, periosteum, soft tissue, lymph node, skin, and infrequently small intestine.
  • It can occur without blood or bone marrow manifestations of leukemia and in this case, the diagnosis is difficult.
  • Our patient was initially diagnosed as a case of T-cell non Hodgkin's lymphoma and received one cycle of CHOP with only transient improvement in his symptoms.
  • Subsequently, his biopsy slides were reviewed at our centre and were reported as granulocytic sarcoma.
  • [MeSH-major] Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy. Bone Marrow / pathology. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Histocytochemistry. Humans. Leukemia, Myeloid, Acute / complications. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Male. Neoplasms. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474271.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


10. Ehrig T, Billings SD, Fanburg-Smith JC: Superficial primitive neuroectodermal tumor/Ewing sarcoma (PN/ES): same tumor as deep PN/ES or new entity? Ann Diagn Pathol; 2007 Jun;11(3):153-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial primitive neuroectodermal tumor/Ewing sarcoma (PN/ES): same tumor as deep PN/ES or new entity?
  • Primitive neuroectodermal tumor/Ewing sarcoma (PN/ES) is a single clinical, morphologic, and molecular small round cell tumor entity.
  • These are generally found in deep soft tissue or bone of young male patients, with poor behavior.
  • Cases coded as "dermal," "cutaneous," or "skin" PN/ES were retrieved from our consultation files.
  • Most cases were small (0.5-2.3 centimeters) and painful, and persisted for less than 1 year.
  • Nine cases with material for reverse transcription-polymerase chain reaction revealed 1 positive type 2 translocation (EWS exon 7 to Fli-1 exon 5), 4 negative, and 4 "unable to amplify."
  • Treatment was by wide excision; 9 received chemotherapy and 6 radiation.
  • Cutaneous PN/ES is a superficial round cell tumor in older women, with better prognosis than deep PN/ES.
  • [MeSH-major] Neuroectodermal Tumors / diagnosis. Neuroectodermal Tumors, Primitive / diagnosis. Sarcoma, Ewing / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / genetics. Antigens, CD / metabolism. Cell Adhesion Molecules / genetics. Cell Adhesion Molecules / metabolism. Child. Child, Preschool. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Sex Characteristics. Vimentin / genetics. Vimentin / metabolism

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498589.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Vimentin
  •  go-up   go-down


11. Yamamoto Y, Teruya K, Katano H, Niino H, Yasuoka A, Kimura S, Oka S: Rapidly progressive human herpesvirus 8-associated solid anaplastic lymphoma in a patient with AIDS--associated Kaposi sarcoma. Leuk Lymphoma; 2003 Sep;44(9):1631-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly progressive human herpesvirus 8-associated solid anaplastic lymphoma in a patient with AIDS--associated Kaposi sarcoma.
  • We report a case of rapidly progressive solid lymphoma with anaplastic large cell morphology, followed by systemic Kaposi sarcoma in an adult patient with AIDS.
  • The lymphoma cells expressed human herpesvirus 8 (HHV-8)-encoded latent and lytic proteins and Epstein-Barr virus-encoded small RNA, suggesting that this case could be categorized into HHV-8-associated solid lymphoma, a recently identified disease entity.
  • [MeSH-major] Gastrointestinal Neoplasms / virology. Herpesvirus 8, Human / isolation & purification. Lymphoma, AIDS-Related / virology. Lymphoma, Large B-Cell, Diffuse / virology. Neoplasms, Second Primary / virology. Sarcoma, Kaposi / virology. Skin Neoplasms / virology. Tumor Virus Infections / virology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / drug therapy. Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Epstein-Barr Virus Infections / complications. Fatal Outcome. HIV-1. Herpesviridae Infections / complications. Herpesvirus 4, Human / isolation & purification. Humans. Lamivudine / therapeutic use. Male. Prednisone / administration & dosage. Ritonavir / therapeutic use. Saquinavir / therapeutic use. Stavudine / therapeutic use. Vincristine / administration & dosage


12. Shingde MV, Buckland M, Busam KJ, McCarthy SW, Wilmott J, Thompson JF, Scolyer RA: Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis. J Clin Pathol; 2009 Oct;62(10):915-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis.
  • AIMS: To perform a clinicopathological analysis of a series of primary cutaneous Ewing sarcomas/primitive neuroectodermal tumours (ES/PNET) to highlight the pathological features, discuss the differential diagnosis, emphasise the role of molecular testing (particularly fluorescence in situ hybridisation, FISH) in diagnosis and outline the patients' clinical course.
  • All cases were characterised histologically by sheet-like growth of small round cells with little cytoplasm and showed strong membranous staining for CD99 and positive but variable staining for FLI-1.
  • Three patients received adjuvant chemotherapy, one of whom also received radiotherapy.
  • CONCLUSIONS: Although rare, primary cutaneous ES/PNET should be considered in the differential diagnosis of cutaneous "small blue cell tumours".
  • Immunostaining for FLI-1 and molecular testing for evidence of an EWS rearrangement are useful ancillary investigations to confirm the diagnosis.
  • [MeSH-major] Neuroectodermal Tumors, Primitive, Peripheral / diagnosis. Sarcoma, Ewing / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence / methods. Male. Melanoma / diagnosis. Microfilament Proteins / metabolism. Middle Aged. Neoplasm Proteins / metabolism. Oncogene Proteins, Fusion / genetics. Prognosis. Proto-Oncogene Protein c-fli-1 / genetics. RNA-Binding Protein EWS / genetics. Receptors, Cytoplasmic and Nuclear / metabolism. Young Adult

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19783720.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / EWS-FLI fusion protein; 0 / FLII protein, human; 0 / Microfilament Proteins; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS; 0 / Receptors, Cytoplasmic and Nuclear
  •  go-up   go-down


13. Taylor GB, Chan YF: Subcutaneous primitive neuroectodermal tumour in the abdominal wall of a child: long-term survival after local excision. Pathology; 2000 Nov;32(4):294-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumours of the peripheral primitive neuroectodermal tumour/Ewing's sarcoma (PNET/ES) family can rarely occur as primary lesions within the skin and subcutis.
  • Histologically it was a small round cell tumour that marked strongly for CD99 and displayed ultrastructual evidence of neural differentiation.
  • The tumour was completely excised, but due to an initial misdiagnosis no adjuvant therapy was given.
  • A review of similar cases reveals not all patients are as fortunate, suggesting combination therapy, including chemotherapy, is still the best treatment for these tumours, even when small and superficial.
  • Our report therefore highlights the importance of recognising PNET/ES in the skin and subcutis so appropriate therapy can be administered.
  • [MeSH-major] Abdominal Muscles / pathology. Muscle Neoplasms / pathology. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Cell Adhesion Molecules / analysis. Cell Nucleus / ultrastructure. Child, Preschool. Disease-Free Survival. Humans. Immunoenzyme Techniques. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11186429.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  •  go-up   go-down


14. Singhal S, Mehta J: Thalidomide in cancer. Biomed Pharmacother; 2002 Feb;56(1):4-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After its success in myeloma, it has been investigated in other plasma cell dyscrasias, myelodysplastic syndromes, gliomas, Kaposi's sarcoma, renal cell carcinoma, advanced breast cancer, and colon cancer.
  • Thalidomide causes responses in 30-50% of myeloma patients as a single agent, and acts synergistically with corticosteroids and chemotherapy.
  • Responses have also been seen in one-third of patients with Kaposi's sarcoma, in a small proportion of patients with renal cell carcinoma and high-grade glioma, and in some patients with colon cancer in combination with irinotecan.
  • The drug is being investigated currently in a number of clinical trials for cancer.
  • Drowsiness, constipation, and fatigue are common side effects, whereas peripheral neuropathy and skin rash are seen in one-third.
  • Thrombotic phenomena are especially common when thalidomide is combined with chemotherapy.
  • Adverse effects severe enough to necessitate cessation of therapy are seen in around 20% of patients.
  • A therapeutic trial of thalidomide is essential in all patients with relapsed or refractory myeloma.
  • In other cancers, the best way to use the drug is in the setting of clinical trials.
  • In the absence of access to studies or alternative therapeutic options, thalidomide could be considered singly or in combination with standard therapy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Neoplasms / drug therapy. Thalidomide / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11905508.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Interleukin-2; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 4Z8R6ORS6L / Thalidomide
  • [Number-of-references] 61
  •  go-up   go-down


15. Somers GR, Shago M, Zielenska M, Chan HS, Ngan BY: Primary subcutaneous primitive neuroectodermal tumor with aggressive behavior and an unusual karyotype: case report. Pediatr Dev Pathol; 2004 Sep-Oct;7(5):538-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primitive neuroectodermal tumor/Ewing sarcoma (PNET/ES) rarely occurs in the skin and subcutaneous tissues.
  • Despite wide local excision and chemotherapy, she rapidly developed cranial bone and brain metastases, followed by lung and skeletal metastases, and died shortly thereafter.
  • The recurrent tumor exhibited light microscopic features of a small, round, blue cell tumor with intracytoplasmic glycogen.
  • [MeSH-major] Neuroectodermal Tumors, Primitive, Peripheral / secondary. Sarcoma, Ewing / pathology. Soft Tissue Neoplasms / pathology. Subcutaneous Tissue / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15547779.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Singhal S, Mehta J: Thalidomide in cancer: potential uses and limitations. BioDrugs; 2001;15(3):163-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been investigated in a number of cancers including multiple myeloma, myelodysplastic syndromes, gliomas, Kaposi's sarcoma, renal cell carcinoma, advanced breast cancer, and colon cancer.
  • It also acts synergistically with corticosteroids and chemotherapy in myeloma.
  • Responses have also been seen in one-third of patients with Kaposi's sarcoma, in a small proportion of patients with renal cell carcinoma and high grade glioma and, in combination with irinotecan, in some patients with colon cancer.
  • Symptoms of peripheral neuropathy and skin rash are seen in 30%.
  • Despite the high frequency of adverse effects, those severe enough to necessitate cessation of therapy are seen in only 10 to 15% of patients.
  • A therapeutic trial of thalidomide should be considered in all patients with myeloma who are unresponsive to or relapse after standard therapy.
  • In other malignant diseases, the most appropriate way to use the drug is in the setting of well designed clinical trials.
  • In the absence of access to such studies, thalidomide could be considered singly or in combination with standard therapy in patients with no meaningful therapeutic options.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Immunosuppressive Agents / therapeutic use. Neoplasms / drug therapy. Thalidomide / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11437682.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide
  • [Number-of-references] 74
  •  go-up   go-down


17. Maity P, Chakraborty S, Bhattacharya P: A general survey of glutamine level in different tissues of murine solid tumor bearing mice before and after therapy with purified glutaminase. J Exp Clin Cancer Res; 2000 Jun;19(2):161-4
Hazardous Substances Data Bank. Glutamine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A general survey of glutamine level in different tissues of murine solid tumor bearing mice before and after therapy with purified glutaminase.
  • Distribution of glutamine level in different tissues of tumor bearing mice such as brain, liver, kidney, spleen, large and small intestine and the tumor itself were studied in three solid tumor models, viz, Ehrlich ascites carcinoma, Sarcoma-180 and methylcholanthrene induced carcinoma.
  • Tumor bearing mice were subjected to therapy for 7 days with the glutaminase purified from malignant S-180 cell.
  • The results exhibit a significant decrease in tumor burden after enzyme therapy.
  • Host tissue glutamine levels were significantly elevated in tumor bearing untreated mice in comparison to the normal ones, while significant lower values were obtained after enzyme therapy.
  • It therefore appears that elevated levels of glutamine in host tissue are associated with the tumor burden.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Glutaminase / therapeutic use. Glutamine / metabolism. Sarcoma 180 / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Brain / metabolism. Intestines / metabolism. Kidney / metabolism. Liver / metabolism. Male. Methylcholanthrene / toxicity. Mice. Spleen / metabolism. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. 3-Methylcholanthrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10965812.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0RH81L854J / Glutamine; 56-49-5 / Methylcholanthrene; EC 3.5.1.2 / Glutaminase
  •  go-up   go-down


18. Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF: Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther; 2010 Nov-Dec;23(6):651-61
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach.
  • Electroporation uses pulsed, high-intensity electric fields to temporarily increase cell membrane permeability by creation of pores, through which small molecules, such as chemotherapeutic agents, can diffuse inside cells before they reseal.
  • The combination of electroporation with the administration of otherwise low-permeant cytotoxic drugs is known as electrochemotherapy (ECT).
  • The two most commonly used drugs are bleomycin and cisplatin.
  • ECT has already been proven to be effective in diverse tumor histotypes, including melanoma and basal and squamous cell carcinoma, Kaposi sarcoma, and breast cancer, also in those cases nonresponding to classical chemotherapies or other loco-regional treatment modalities, with a good safety profile.
  • ECT can be proposed as loco-regional therapy for disseminated cutaneous and subcutaneous tumor lesions as alternative treatment modality to conventional therapies or as palliative care, in order to improve patients' quality of life.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Electrochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Humans. Skin / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley Periodicals, Inc.
  • (PMID = 21054709.001).
  • [ISSN] 1529-8019
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Satzger I, Völker B, Kofahl-Krause D, Ganser A, Kapp A, Gutzmer R: [Intravascular lymphoma: two case reports demonstrating the heterogeneity of the disease]. Hautarzt; 2009 Feb;60(2):131-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intravascular lymphoma (IVL) is a rare subtype of extranodal large-B-cell lymphoma, histologically characterized by accumulation of clonal lymphocytes in small vessels of different organs.
  • Cutaneous and neurological involvement is frequent; the cutaneous symptoms are heterogeneous with erythema, erythematous papules and plaques, generalized telangiectases and lesions resembling panniculitis or Kaposi sarcoma.
  • IVL may also be limited to the skin; this entity is included the current classifications.
  • One showed only skin involvement with panniculitis-like induration and responded well to therapy with Rituximab-CHOP (Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone).
  • The other patient had distinctive cutaneous and neurological symptoms which did not respond to therapy.
  • By means of these two patients, we present the heterogeneity of IVL and discuss current aspects of diagnosis and treatment.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Panniculitis / diagnosis. Panniculitis / drug therapy. Vascular Neoplasms / diagnosis. Vascular Neoplasms / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Aug;18(8):1121-6 [15803190.001]
  • [Cites] Arch Neurol. 2002 Mar;59(3):439-43 [11890850.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Oncologist. 2006 May;11(5):496-502 [16720850.001]
  • [Cites] J Cutan Med Surg. 2003 Nov-Dec;7(6):460-3 [14605917.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):173-83 [15461623.001]
  • [Cites] J Neurol. 2000 Aug;247(8):656-8 [11041340.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1713-22 [17540844.001]
  • [Cites] J Am Acad Dermatol. 2002 Nov;47(5 Suppl):S260-2 [12399744.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1197-201 [16931967.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):89-91 [11244443.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):337-41 [16321868.001]
  • [Cites] Hautarzt. 1963 Feb;14:67-70 [13984914.001]
  • [Cites] Ann Hematol. 2004 Sep;83(9):608-10 [15205915.001]
  • [Cites] Br J Dermatol. 1997 Sep;137(3):422-5 [9349342.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2321-2 [11187923.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):233-4 [16284609.001]
  • (PMID = 18654750.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down






Advertisement